Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Schreiber RD, Old LJ, Smyth MJ.

Science. 2011 Mar 25;331(6024):1565-70. doi: 10.1126/science.1203486. Review.

PMID:
21436444
2.

Cancer immunoediting: from immunosurveillance to tumor escape.

Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD.

Nat Immunol. 2002 Nov;3(11):991-8. Review.

PMID:
12407406
3.

The immune system--is it relevant to cancer development, progression and treatment?

Prestwich RJ, Errington F, Hatfield P, Merrick AE, Ilett EJ, Selby PJ, Melcher AA.

Clin Oncol (R Coll Radiol). 2008 Mar;20(2):101-12. Epub 2007 Nov 26. Review.

PMID:
18037277
4.

Commentary: Immune escape versus tumor tolerance: how do tumors evade immune surveillance?

Salih HR, Nüssler V.

Eur J Med Res. 2001 Aug 27;6(8):323-32. Review.

PMID:
11549514
5.

Signaling defects in anti-tumor T cells.

Frey AB, Monu N.

Immunol Rev. 2008 Apr;222:192-205. doi: 10.1111/j.1600-065X.2008.00606.x. Review.

6.

Tumor immunoediting and immunosculpting pathways to cancer progression.

Reiman JM, Kmieciak M, Manjili MH, Knutson KL.

Semin Cancer Biol. 2007 Aug;17(4):275-87. Epub 2007 Jun 26. Review.

7.

Anti-tumor immunity: myeloid leukocytes control the immune landscape.

Rutkowski MR, Stephen TL, Conejo-Garcia JR.

Cell Immunol. 2012 Jul-Aug;278(1-2):21-6. doi: 10.1016/j.cellimm.2012.06.014. Epub 2012 Jul 14. Review.

8.

Natural innate and adaptive immunity to cancer.

Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ.

Annu Rev Immunol. 2011;29:235-71. doi: 10.1146/annurev-immunol-031210-101324. Review.

PMID:
21219185
9.

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.

Mittal D, Gubin MM, Schreiber RD, Smyth MJ.

Curr Opin Immunol. 2014 Apr;27:16-25. doi: 10.1016/j.coi.2014.01.004. Epub 2014 Feb 14. Review.

10.

Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells.

Hurwitz AA, Watkins SK.

Cancer Immunol Immunother. 2012 Feb;61(2):289-93. doi: 10.1007/s00262-011-1181-5. Epub 2012 Jan 12. Review.

11.

Natural immunity to cancer in humans.

Bindea G, Mlecnik B, Fridman WH, Pagès F, Galon J.

Curr Opin Immunol. 2010 Apr;22(2):215-22. doi: 10.1016/j.coi.2010.02.006. Epub 2010 Mar 6. Review.

PMID:
20207124
12.

Tumour immunology: alternative perspectives.

Seljelid R.

Scand J Immunol. 1997 Nov;46(5):437-44. Review. No abstract available.

13.

Cancer immunoediting and "spontaneous" tumor regression.

Sengupta N, MacFie TS, MacDonald TT, Pennington D, Silver AR.

Pathol Res Pract. 2010 Jan 15;206(1):1-8. doi: 10.1016/j.prp.2009.10.001. Epub 2009 Nov 27. Review.

PMID:
19945228
14.

The critical role of type-1 innate and acquired immunity in tumor immunotherapy.

Ikeda H, Chamoto K, Tsuji T, Suzuki Y, Wakita D, Takeshima T, Nishimura T.

Cancer Sci. 2004 Sep;95(9):697-703. Review.

15.

T-cell death and cancer immune tolerance.

Lu B, Finn OJ.

Cell Death Differ. 2008 Jan;15(1):70-9. Epub 2007 Nov 16. Review.

16.

Challenges and prospects of immunotherapy as cancer treatment.

Rescigno M, Avogadri F, Curigliano G.

Biochim Biophys Acta. 2007 Sep;1776(1):108-23. Epub 2007 Jul 17. Review.

PMID:
17720322
17.

[Antitumor immunity and cellular cancer therapies].

Catros-Quemener V, Bouet F, Genetet N.

Med Sci (Paris). 2003 Jan;19(1):43-53. Review. French.

18.

Cancer immunoprevention: a new approach to intercept cancer early.

Umar A.

Cancer Prev Res (Phila). 2014 Nov;7(11):1067-71. doi: 10.1158/1940-6207.CAPR-14-0213. Epub 2014 Sep 18. Review.

19.

Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?

Malmberg KJ.

Cancer Immunol Immunother. 2004 Oct;53(10):879-92. Epub 2004 Jul 28. Review.

PMID:
15338206
20.

Regulatory T cells and innate immune regulation in tumor immunity.

Wang RF.

Springer Semin Immunopathol. 2006 Aug;28(1):17-23. Epub 2006 Jul 13. Review. Erratum in: Springer Semin Immunopathol. 2006 Aug;28(1):77.

PMID:
16838179

Supplemental Content

Support Center